Expert guidelines for wearables and genetic risk scores
Part of Heart & circulation clinical trials.
This trial aims to develop guidelines for using wearable devices and polygenic risk scores (genetic tests that estimate disease risk) in heart care. It brings together experts to create recommendations that could improve patient care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a recognized expert in cardiology, personalized medicine, or digital health.
- You must be willing to provide informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a polygenic risk score to see if knowing your genetic risk for coronary artery disease can help prevent a first heart attack. If you have an intermediate 10-year risk and no prior heart events, you may be eligible.
This trial looks at how learning about your genetic risk for heart disease might help prevent it. You will get a personalized report and guidance.
This trial looks at an individualized prevention approach for people who are at higher risk of heart and blood vessel problems. It aims to help lower future cardiovascular risk before heart disease develops.
This study tests new, personalized ways to prevent heart disease in people with metabolic syndrome. It aims to see if custom approaches can lower your risk of heart attacks and strokes.
This study follows people to understand heart disease risk by combining a heart risk score with genetic risk (polygenic risk). It may help improve how doctors identify who is at higher risk and could guide prevention planning.
This study is testing whether a special blood test (genomic predictor) can help doctors better manage heart and kidney risks in people with type 2 diabetes. You may benefit from learning your personal risk score and getting more tailored care.
Hear when a new Wearable Electronic Devices trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.